Black Rock Inc. Cti Biopharma Corp Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$4.2 - $6.01 $177,689 - $254,265	42,307 Added 0.6%	7,102,626 $29.8 Million
Q4 2022 Feb 13, 2023	BUY	$4.45 - $6.17 $2.05 Million - $2.85 Million	461,546 Added 6.99%	7,060,319 $42.4 Million
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $3.79 Million - $5.26 Million	707,804 Added 12.02%	6,598,773 $38.4 Million
Q2 2022 Aug 12, 2022	BUY	$3.55 - $6.27 $14.6 Million - $25.7 Million	4,099,276 Added 228.79%	5,890,969 $35.2 Million
Q1 2022 May 12, 2022	SELL	$1.9 - $5.23 $13,560 - $37,326	-7,137 Reduced 0.4%	1,791,693 $8.37 Million
Q4 2021 Feb 10, 2022	BUY	$1.44 - $2.86 $1.3 Million - $2.58 Million	903,439 Added 100.9%	1,798,830 $4.46 Million
Q3 2021 Nov 09, 2021	SELL	$2.25 - $3.18 $3,735 - $5,278	-1,660 Reduced 0.19%	895,391 $2.64 Million
Q2 2021 Aug 11, 2021	BUY	$2.16 - $2.62 $1.94 Million - $2.35 Million	897,051 New	897,051 $2.24 Million

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.